Target Selector kits are research-use-only (RUO), to enable labs to leverage Biocept's patented assay technology for liquid biopsy testing
SGEN adds CASC's late stage breast cancer therapeutic pipeline.
The full IPO calendar is available at IPOpremium.com Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cells and circulating tumor DNA assays utilizing a standard blood sample. The company's lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.
| Website: | www.biocept.com |
| Email: | ir@biocept.com |
| Main Phone: | +1 858 320-8200 |
| Address: | 5810 Nancy Ridge Drive |
| Address 2: | Suite 150 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Michael W. Nall |
| Employees: | 95 |
| NAICS: | Medical Laboratories(621511) |
Target Selector kits are research-use-only (RUO), to enable labs to leverage Biocept's patented assay technology for liquid biopsy testing
SGEN adds CASC's late stage breast cancer therapeutic pipeline.
The full IPO calendar is available at IPOpremium.com Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the
Biocept (BIOC) is an early-stage cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a
At www.ValuEngine.com we show that the Medical sector is 9.8% overvalued. The Medical Products industry is 4.2% overvalued. The Medical Services industry is 9.1% overvalued. The Medical
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
